Get the Stockscreener App
123.11
2.14%
2.58
Jazz Pharmaceuticals Plc stock is traded at $123.11, with a volume of 725.10K.
It is up +2.14% in the last 24 hours and up +5.82% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$120.53
Open:
$122.01
24h Volume:
725.10K
Relative Volume:
0.95
Market Cap:
$7.47B
Revenue:
$3.99B
Net Income/Loss:
$463.16M
P/E Ratio:
17.34
EPS:
7.1
Net Cash Flow:
$1.10B
1W Performance:
+4.53%
1M Performance:
+5.82%
6M Performance:
-9.48%
1Y Performance:
+7.47%
1-Day Range:
$121.40
$124.04
1-Week Range:
$117.10
$124.04
52-Week Range:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
123.11 | 7.14B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Initiated | Deutsche Bank | Buy |
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Chart overlay techniques for tracking Jazz Pharmaceuticals plcMarket Sentiment Report & Reliable Price Action Trade Plans - Newser
Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal - insights.citeline.com
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 - WV News
Jazz pharmaceuticals acquires rights to Saniona’s epilepsy drug candidate By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals, Saniona Enter Exclusive Agreement - Contract Pharma
Why Jazz Pharmaceuticals (JAZZ) Is Up 5.2% After Modeyso Receives FDA Approval for Rare Brain Cancer - simplywall.st
Jazz pharmaceuticals acquires rights to Saniona’s epilepsy drug candidate - Investing.com
Jazz Pharmaceuticals licenses epilepsy drug from Saniona for $42.5M - StreetInsider
$1 Billion Deal: Jazz Pharma Secures Rights to Revolutionary Epilepsy Drug SAN2355 from Saniona - Stock Titan
Jazz Pharmaceuticals price target lowered to $165 from $166 at Morgan Stanley - MSN
Risk vs reward if holding onto Jazz Pharmaceuticals plcInflation Watch & Community Shared Stock Ideas - Newser
Has Jazz Pharmaceuticals plc formed a bullish divergenceMarket Rally & Free Risk Controlled Daily Trade Plans - Newser
Pattern recognition hints at Jazz Pharmaceuticals plc upsideJuly 2025 Pullbacks & Safe Entry Point Identification - Newser
Price action breakdown for Jazz Pharmaceuticals plcDollar Strength & Fast Moving Stock Trade Plans - Newser
Ligand to Participate in September Investor Conferences - GlobeNewswire Inc.
Using flow based indicators on Jazz Pharmaceuticals plcMarket Performance Summary & Low Risk High Win Rate Stock Picks - Newser
Jazz Pharmaceuticals plc Shows Early Signs of Technical Strength2025 Pullback Review & Expert Verified Movement Alerts - kangso.co.kr
Jazz Pharma gets FDA priority review for lung cancer therapy Zepzelca - MSN
AI Trend Models Suggest Bounce for Jazz Pharmaceuticals plcPortfolio Gains Report & Technical Pattern Based Buy Signals - 선데이타임즈
Will Jazz Pharmaceuticals plc bounce back from current supportMarket Growth Review & Low Drawdown Investment Ideas - Newser
AI Indicators Detect Buy Opportunity in Jazz Pharmaceuticals plcWeekly Trend Recap & AI Forecasted Entry and Exit Points - newsimpact.co.kr
Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks - Yahoo Finance
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt - 富途牛牛
Jazz Pharma wins FDA nod for Modeyso against rare brain tumor - MSN
Bollinger Band Squeeze Points to Volatility in Jazz Pharmaceuticals plc2025 Historical Comparison & Weekly Hot Stock Watchlists - classian.co.kr
Jazz Pharmaceuticals plc Approaches Psychological Resistance LevelEarnings Miss & Trade Opportunity Analysis Reports - sisa-n.com
Developing predictive dashboards with Jazz Pharmaceuticals plc dataMarket Activity Report & Reliable Volume Spike Alerts - Newser
Is Jazz Pharmaceuticals plc stock entering bullish territoryRate Hike & Low Risk Entry Point Tips - Newser
Using data tools to time your Jazz Pharmaceuticals plc exitExit Point & Reliable Price Breakout Alerts - Newser
Combining machine learning predictions for Jazz Pharmaceuticals plcWeekly Loss Report & Free Long-Term Investment Growth Plans - Newser
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Jazz Pharmaceuticals plc Earnings Report Breakdown: What Investors Should Know2025 Volatility Report & AI Powered Market Trend Analysis - Newser
Jazz Pharmaceuticals plc stock trend outlook and recovery pathPortfolio Return Summary & Verified Swing Trading Watchlists - Newser
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Published on: 2025-08-16 00:17:35 - thegnnews.com
BofA Securities raises Jazz Pharmaceuticals stock price target on Modeyso potential - Investing.com Nigeria
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
XTX Topco Ltd Acquires New Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) - Defense World
United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 20337.88% CAGR Driven by Novel Therapies and Better Diagnosis - Yahoo Finance
JAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook - Yahoo Finance
Is FDA’s First-Ever Approval of Modeyso Shaping the Investment Case for Jazz Pharmaceuticals (JAZZ)? - simplywall.st
The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
PNC Financial Services Group Inc. Raises Stock Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) - Defense World
How Jazz Pharmaceuticals plc stock performs during market volatilityShort-Term Stock Trend Forecast Guide - Newser
Cetera Investment Advisers Acquires 444 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) - Defense World
Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance - MSN
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
Mutual of America Capital Management LLC Has $3.86 Million Stock Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) - Defense World
Avantax Advisory Services Inc. Lowers Stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) - Defense World
What data driven models say about Jazz Pharmaceuticals plc’s futureEntry Opportunity Screener with Confirmation - Newser
Jazz Pharmaceuticals gets EU nod for Ziihera - MSN
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):